We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




First Saliva Diagnostic Test for Endometriosis Delivers Reliable Results Within Days

By LabMedica International staff writers
Posted on 12 Feb 2025

Endometriosis affects approximately 1 in 10 women globally, with a range of symptoms that can severely impact their health, quality of life, and fertility. More...

The delay in diagnosis, which can take between 7 to 10 years, is a significant barrier to improving care, life quality, and fertility outcomes. Now, a pioneering saliva-based diagnostic test for endometriosis offers new possibilities for early and non-invasive diagnosis of this painful disease.

The Ziwig Endotest, developed by Ziwig (Lyon, France), is a saliva test for endometriosis that provides a reliable diagnosis within just a few days. Ziwig is transforming the diagnosis and treatment of women's health conditions by harnessing the power of salivary RNA. The Ziwig Endotest is the first-ever application of salivary microRNA1-6 in gynecology. This test requires only a simple saliva sample, with the diagnosis performed in the laboratory. It is based on high-throughput sequencing of the microRNA found in saliva, combined with artificial intelligence (AI) to process the large volumes of data generated. Using the Ziwig Endotest, a diagnosis can be made in just a few days with exceptional accuracy (97.4% sensitivity, 93.7% specificity). The test enables clinicians to reliably confirm or exclude a diagnosis of endometriosis and distinguish it from other conditions with similar symptoms. It is particularly useful in complex cases where medical imaging may be inconclusive.

Ziwig’s non-invasive approach to saliva sampling, along with technological advancements in sequencing and AI, makes accurate, early diagnosis of endometriosis more accessible. The company’s focus on the RNA and extracellular vesicles in saliva represents a milestone in personalized medicine. The Ziwig Endotest offers a breakthrough biological test for healthcare providers and patients by reducing diagnostic delays, identifying complex and early-stage cases sooner, providing an alternative to invasive procedures, and enhancing fertility preservation through earlier diagnosis.

"With Ziwig Endotest we are determined to end the unacceptable diagnostic wandering that leaves many women in pain,” said Yahya El Mir, Ziwig CEO-Founder.

Related Links:
Ziwig


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hybrid Pipette
SWITCH
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.